HIFU Treatment of Cutaneous Neurofibromas in Neurofibromatosis Type 1: Safety and Efficacy (cNF-HFU2101)

• ClinicalTrials.gov Identifier: NCT05119582
• Recruitment Status: Active, not recruiting
• First Posted: November 15, 2021
• Last Update Posted: June 24, 2022
• Sponsor: Joergen Serup
• Collaborator: Sahlgrenska University Hospital, Sweden
• Information provided by (Responsible Party): Joergen Serup, Bispebjerg Hospital

Study Description

Brief Summary:

The overall objective is to demonstrate safety and efficacy of HIFU treatment of cutaneous neurofibromas located close to the surface of the skin in patients with the genetic disease Neurofibromatosis Type 1. The study will use a new investigational equipment that has been specially developed for dermatological therapy.

The study includes 20 patients in total distributed between the two centers, each having a minimum of 8 cutaneous neurofibromas eligible for treatment. All participants are adults (over 18 years) of both sexes.

The new treatment method is based on focusing intensive ultrasound just below the skin surface. This creates a very fast localized heating in small and very well-defined volumes containing neurofibroma tissue. This heating destroys or weakens the tissue, and the body's natural processes will subsequently transport affected cells away through the lymphatic and vascular systems. During the healing-process, the rejected tissue is replaced by new skin cells that are not expected to be fibrous.

The treatment is intended to be carried out without breaking the skin surface, and open wounds are therefore avoided. This is an essential advantage of the method compared to all existing therapies, which are based on physical removal of tumors through an open skin surface (e.g. surgery or laser therapy). Complications with risk of pain, infection and scarring will therefore be significantly reduced with the new proposed method.

The treatment is carried out by sending focused ultrasound from the handpiece of the equipment into the target area with neurofibromas. The equipment is set to send doses of approximately 150 milliseconds (0.15 seconds). The skin area and HIFU doses can be followed on the system computer screen and will be placed side-by-side with approximately 1-2 millimeter spacing. To achieve good energy transfer from handpiece to skin, ordinary ultrasound gel is used. There are no other special pre-treatments or preparations for the process. HIFU treatment is expected to be less painful than other treatments used. The treatment is quick, and typically takes less than 1 minute for a each area the size of a typical neurofibroma.

Condition or disease	Intervention/treatment	Phase
Cutaneous Neurofibroma	Device: TOOsonix System ONE-M	Not Applicable

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 20 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment

Intervention Model Description

The study is a multicenter (two-center) open-label study with high-intensity focused ultrasound (HIFU) treatment of patients with the genetic disease Neurofibromatosis Type1.

The study is not comparative or randomized. The investigation is performed prior to CE mark to confirm safety and performance of the System ONE-M device when used as intended, i.e. as an non-invasive method to remove cutaneous neurofibromas by 20 MHz high intensity focused ultrasound.

• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: High-Intensity Focused Ultrasound (HIFU), a Novel Method for Treatment of Cutaneous Neurofibromas in Neurofibromatosis Type 1: Safety and Efficacy
• Actual Study Start Date: April 13, 2022
• Estimated Primary Completion Date: January 1, 2024
• Estimated Study Completion Date: January 1, 2024

Arms and Interventions

Arm	Intervention/treatment
Experimental: TOOsonix System ONE-M; Cutaneous neurofibromas will be treated by high intensity focused ultrasound.	Device: TOOsonix System ONE-M; Selected neurofibromas will be treated by high intensity focused ultrasound. Untreated fibromas will be used for controls.

Outcome Measures

Primary Outcome Measures :

1. Short Term Safety Profile - Adverse Events [ Time Frame: 3 months ]

   The grade of any adverse events (AE) requiring medical intervention within three months of treatment should be low. Device-based treatment will be considered tolerable if less than 30% of participants treated have an "Overall AE Score" larger than Grade 2 AE at the 3-month follow-up (visit 4).

   Measured by a grading scale based on Common Terminology Criteria for Adverse Events (CTCAE), U.S. Department of health and human services, Ver 5.0, Nov 27, 2017.

2. Long Term Safety Profile - Healing [ Time Frame: 9 months ]

   The rate and nature of spontaneous healing of the treated cNF lesion and any safety related event including potential wound formation and wound healing should be equivalent to expectations from alternative method(s). Safety evaluation includes rating of treatment-associated sequele by end of study, e.g. dyspigmentation and scarring and overall investigator rating compared to expectations.

   Measured on 5-point grading from Very Unsatisfied to Very Satisfied.

Secondary Outcome Measures :

1. Long Term Safety Profile - Adverse Events [ Time Frame: 9 months ]

   Any objective adverse effect or event, local or systemic, related to the treatment and the investigational device.

   Measured by a grading scale based on Common Terminology Criteria for Adverse Events (CTCAE), U.S. Department of health and human services, Ver 5.0, Nov 27, 2017.

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Males and females 18 years of age or older.
• Patients with a clinical diagnosis of NF1 based on germline genetic testing or by meeting the internationally recognized criteria given by the Clinical Care Advisory Board of the National Neurofibromatosis Foundation (now the Children's Tumor Foundation)
• Patients must be seeking active treatment for cNF.
• Patients must have ≥ 8 paired cNF that are visible and measure a minimum of 2 mm in size. These must be in areas amenable to treatment and surveillance.
• Patients with Fitzpatrick Type I to VI skin-type
• Able and willing to comply with all visits, treatments, evaluations, schedules, and requirements.
• Patients shall have received oral and written study information, accepted participation and signed the informed consent document.
• Patients who are willing and mentally and physically capable to understand and follow the treatment and follow-up schedule including post-treatment care instructions.
• Patients who are willing to have photographs and images taken of the treated lesions to be used anonymously or coded in evaluations and publications.

Exclusion Criteria:

• Patients who are undergoing other treatment modalities or investigational agents for their cNF lesions.
• Individuals who cannot give informed consent or adhere to study schedule.
• Patients who are actively tanning during the course of the study.
• Patients with adverse reactions to compounds of any external agent in use.
• Patients with known allergy to injectable anesthetics (relevant for biopsy only).
• Patients with any condition which, in the Investigator's opinion, would make it unsafe (for the participant or study personnel) to treat the participant as part of this research study.
• Patients, where target treatment may cause the acoustic beam to enter the eye.
• Pregnant females, due to possible discomfort with the procedure even though the procedure is localized and there is no new drug.
• Patients with tendency for keloid and hypertrophic scar formation .
• Patients with impaired wound healing.
• Patients with any other acute or chronic condition which, in the opinion of the investigator, could interfere with the conduct of the study.

Contacts and Locations

Locations

Denmark

Bispebjerg Hospital

Copenhagen, Hovedstaden, Denmark, 2400

Sweden

Sahlgrenska University Hospital

Gothenburg, Sweden, 41318

Sponsors and Collaborators

Joergen Serup

Sahlgrenska University Hospital, Sweden

More Information

• Responsible Party: Joergen Serup, Professor, Chief Physician, Department of Dermatology, Bispebjerg Hospital
• ClinicalTrials.gov Identifier: NCT05119582
• Other Study ID Numbers: CIV-21-09-037759
• First Posted: November 15, 2021
• Last Update Posted: June 24, 2022
• Last Verified: June 2022

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:

Neurofibromatoses; Neurofibromatosis 1; Neurofibroma; Nerve Sheath Neoplasms; Neoplasms, Nerve Tissue; Neoplasms by Histologic Type; Neoplasms; Neoplastic Syndromes, Hereditary; Neurocutaneous Syndromes; Nervous System Diseases; Heredodegenerative Disorders, Nervous System; Neurodegenerative Diseases; Genetic Diseases, Inborn; Peripheral Nervous System Diseases; Neuromuscular Diseases; Peripheral Nervous System Neoplasms; Nervous System Neoplasms